Skip to main content

Dafna Gladman

Dafna D Gladman is Professor of Medicine at the University of Toronto, Canada. She is a senior rheumatologist, deputy director of the Centre for Prognosis Studies in the Rheumatic Diseases, director of the Psoriatic Arthritis Program, co-director of the University of Toronto Lupus Clinic, and a senior scientist at the Krembil Research Institute at Toronto Western Hospital.

Dr Gladman helped establish the Group for the Research and Assessment of Psoriasis and Psoriatic Arthritis, and was its first president from 2006–2009. In 2007, Dr Gladman established the International Psoriasis and Arthritis Research Team (IPART). Dr Gladman is a co-principal investigator, executive committee member, and incumbent treasurer of the Spondyloarthritis Research Consortium of Canada; a research program that aims to achieve significant improvement in outcomes for Canadians with spondyloarthritis.

Dr Gladman’s research program includes clinical and laboratory research in both psoriatic arthritis and systemic lupus erythematosus. She has authored 797 peer-reviewed publications, 138 chapters and invited publications, two books, and has edited three other books.

Dr Gladman received the Mentor of the Year Award from the Royal College of Physicians and Surgeons of Canada, was awarded the Carol Nachman Prize for innovative research in inflammatory arthritis, and the Distinguished Clinical Investigator Award from the American College of Rheumatology.

print
PRINT

Latest contributions from Dafna Gladman

Guidelines podcast

01-11-2019 | Psoriatic arthritis | Podcast | Article

Discussing the guidelines for managing psoriatic arthritis: Part 2

In the second of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the implications and limitations of the recent ACR–NPF guidelines for the management of psoriatic arthritis, together with key clinical trials that have been published since the guidelines were released.

Guidelines podcast

18-10-2019 | Psoriatic arthritis | Podcast | Article

Discussing the guidelines for managing psoriatic arthritis: Part 1

In the first of a two-part series, Dafna Gladman, Philip Mease, and Oliver FitzGerald discuss the development of the recent ACR–NPF guidelines for the management of psoriatic arthritis, and the key differences between these and the EULAR and GRAPPA guidelines.

Pills in hand

21-02-2019 | Psoriatic arthritis | Feature | Article

The role of JAK inhibitors in the treatment of PsA

Dafna Gladman speaks to medwireNews about the trial data supporting the use of Janus kinase inhibitors in patients with psoriatic arthritis, and discusses the impact these agents may have.